Nevertheless, the data provided support that the CYP2C8*2 variant studied does not lead to toxic plasma levels of chloroquine associated with significant cardiac abnormalities when used in the doses typically prescribed for the treatment of malaria. This evidence concerns the gene CYP2C8 and malaria.